United Therapeutics CEO Martine Rothblatt sells 9,500 shares for about $5.5 million under trading plan

United Therapeutics Chair and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares on Oct. 23, for about $5.54 million, according to a Form 4 filed Monday.

The trades were made through a trust under a Rule 10b5-1 trading plan, which lets executives schedule sales in advance.

The trades

According to the filing, Rothblatt exercised options at $117.76 per share that were due to expire March 15, 2027. The 9,500 shares were sold the same day in multiple trades at prices from $577.08 to $588.39.

The footnotes say she adopted the plan on Nov. 7, 2025. It covers exercising options and selling the underlying shares, and it ends when all 1,734,410 options covered by the plan have been exercised and sold, or on Dec. 31, 2026, whichever comes first.

Remaining holdings

After the sales, the trust held 324,443 shares of United Therapeutics common stock indirectly and 166,910 options from the series she exercised, the filing shows.

Key facts

• Insider: Martine Rothblatt, chair and CEO
• Trade date: Oct. 23, 2026
• Options exercised: 9,500 at $117.76
• Sale price range: $577.08 to $588.39
• Approximate proceeds: $5.54 million
• Rule 10b5-1 plan: adopted Nov. 7, 2025

Sources

1. United Therapeutics Corporation, Form 4 for Martine Rothblatt, filed Oct. 26, 2026 (accession 0001106578-26-000171)

This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.

Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.